Luis Ortega-Paz interviews C. Michael Gibson about the AEGIS-II primary trial results which he presented at ACC.24 in Atlanta.

ApoA-I post-heart attack showed no reduction in 90-day death or heart attack risk. However, exploratory analysis hints at benefits at one year, suggesting potential for longer-term efficacy.

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

Conduction disturbances remain the most common complications of TAVI and its main drawback compared to surgery. How would you treat this 82-year-old man, height 1.68 m, weight 112 kg, with peripheral artery disease, who presented with severe aortic stenosis and symptoms of NYHA Class 3 breathlessness?

Elad Asher provides his take on the ULTIMATE-DAPT Trial results which Gregg W Stone presented at ACC.24 in Atlanta.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2024 Scientific Sessions #ACC24

Elad Asher reviews the EROSION III trial, presented by Haibo Jia, which studied whether OCT guidance compared with angiographic guidance only is associated with lower stent rate implantation during pPCI in STEMI patients with non-obstructive stenosis.

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Nicola Ryan reviews the iFR Swedeheart multicenter, randomized, controlled, open-label clinical trial using the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) for enrolment randomisation and follow up. At one year follow up iFR guided revascularisation was shown to be non-inferior to FFR guided revascularisation, these results...

What is it exactly? The aortic annulus is a fibrous ring at the aortic orifice to the front and right of the atrioventricular aortic valve and is considered the transition point between the left ventricle and aortic root.

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Alex Sticchi provides his take on the PASCAL IID Registry and an initial comparison with the CLASP IID. The trial was presented by Jörg Hausleiter during TCT Congress 2022.

Jonathan Curio provides his take on TOP-CABG, presented by Xin Yuan at ESC Congress 2025 in Madrid.

Nicola Ryan provides a PICOT analysis of PACMAN AMI: a double-blind, placebo-controlled, randomized trial presented at ACC 2022 and simultaneously published in JAMA.

Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation. 

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.